Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas

Giuliana Cavalloni, Caterina Peraldo-Neia, Ivana Sarotto, Loretta Gammaitoni, Giorgia Migliardi, Marco Soster, Serena Marchiò, Massimo Aglietta, Francesco Leone

Research output: Contribution to journalArticlepeer-review


Biliary tract carcinoma (BTC) has a poor prognosis due to limited treatment options. There is, therefore, an urgent need to identify new targets and to design innovative therapeutic approaches. Among potential candidate molecules, we evaluated the nonreceptor tyrosine kinase Src, observing promising antitumor effects of its small-molecule inhibitor saracatinib in BTC preclinical models. The presence of an active Src protein was investigated by immunohistochemistry in 19 surgical samples from patients with BTC. Upon saracatinib treatment, the phosphorylation of Src and of its downstream transducers was evaluated in the BTC cell lines TFK-1, EGI-1, HuH28, and TGBC1-TKB. The effect of saracatinib on proliferation and migration was analyzed in these same cell lines, and its antitumor activity was essayed in EGI-1 mouse xenografts. Saracatinib-modulated transcriptome was profiled in EGI-1 cells and in tumor samples of the xenograft model. Src was activated in about 80% of the human BTC samples. In cultured BTC cell lines, low-dose saracatinib counteracted the activation of Src and of its downstream effectors, increased the fraction of cells in G 0-G 1 phase, and inhibited cell migration. At high concentrations (median dose from 2.26-6.99 μmol/L), saracatinib was also capable of inhibiting BTC cell proliferation. In vivo, saracatinib treatment resulted in delayed tumor growth, associated with an impaired vascular network. Here,weprovide a demonstration that the targeted inhibition of Src kinase by saracatinib is of therapeutic benefit in preclinical models of BTC.Wepropose our results as a basis for the design of saracatinib-based clinical applications.

Original languageEnglish
Pages (from-to)1528-1538
Number of pages11
JournalMolecular Cancer Therapeutics
Issue number7
Publication statusPublished - Jul 2012

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas'. Together they form a unique fingerprint.

Cite this